Compare NEXA & AAPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NEXA | AAPG |
|---|---|---|
| Founded | 1956 | 2009 |
| Country | Luxembourg | China |
| Employees | N/A | 767 |
| Industry | Metal Mining | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 2.0B |
| IPO Year | 2017 | N/A |
| Metric | NEXA | AAPG |
|---|---|---|
| Price | $14.79 | $19.64 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | $10.40 | ★ $48.40 |
| AVG Volume (30 Days) | ★ 1.7M | 2.9K |
| Earning Date | 05-06-2026 | 05-20-2026 |
| Dividend Yield | ★ 0.93% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $8.69 | $290.34 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.62 | $19.66 |
| 52 Week High | $16.89 | $48.45 |
| Indicator | NEXA | AAPG |
|---|---|---|
| Relative Strength Index (RSI) | 53.17 | 29.78 |
| Support Level | $13.81 | N/A |
| Resistance Level | $14.84 | $25.23 |
| Average True Range (ATR) | 1.10 | 0.55 |
| MACD | -0.15 | -0.27 |
| Stochastic Oscillator | 51.58 | 9.20 |
Nexa Resources SA operate large-scale, mechanized underground and open pit mines, as well as smelters. The company operates through two segments namely Mining and Smelting. Its Mining segment consists of various operating units includes mineral exploration activities and the production of zinc concentrates, copper concentrates and concentrates. The Smelting segment comprises operating units which include facilities recovering and refining zinc metal out of feed materials such as zinc concentrates or secondary feed materials. It generates maximum revenue from the Smelting segment. Geographically It has a presence in Brazil, Peru, the United States of America, Switzerland, Japan, Argentina, South Korea, Colombia, Vietnam, Malaysia and other countries.
Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The Group has one reportable operating segment, which is discovering, developing, and commercializing therapies to address medical needs in hematological malignancies and currently has seven drug candidates in pipeline under research. The company's geographical segments include the United States and Mainland China.